Intech Biopharm Ltd Total Liabilities

Latest as of March 2026: NT$1.34 Billion TWD ≈ $42.09 Million USD

Intech Biopharm Ltd total liabilities. Based on the latest financial reports, Intech Biopharm Ltd (6461) has total liabilities worth NT$1.34 Billion TWD (≈ $42.09 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Intech Biopharm Ltd's assets to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Intech Biopharm Ltd (2017–2025)

Total liabilities of Intech Biopharm Ltd from 2017 to 2025. This chart illustrates how Intech Biopharm Ltd's total liabilities have evolved over time, based on quarterly financial data.

Intech Biopharm Ltd Competitors by Total Liabilities

The table below lists competitors of Intech Biopharm Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Emvision Medical Devices Ltd AU:EMV	Australia	AU$5.20 Million
Solborn Inc KQ:035610	Korea	₩72.77 Billion
Pantages Capital Acquisition Corporation. NASDAQ:PGAC	USA	$1.44 Million
Anixa Biosciences Inc NASDAQ:ANIX	USA	$1.87 Million
Hsin Ba Ba Corp TW:9906	Taiwan	NT$7.32 Billion
Softstar Entertainment TWO:6111	Taiwan	NT$21.04 Billion
Spheria Emerging Companies Ltd AU:SEC	Australia	AU$1.17 Million
AKA Brands Holding Corp NYSE:AKA	USA	$303.27 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Intech Biopharm Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 6461 total assets.

Liquidity & Leverage Metrics

Intech Biopharm Ltd Total Liabilities Ratios Explained

Intech Biopharm Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	0.96	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.35	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.57	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Intech Biopharm Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Intech Biopharm Ltd (2017–2025)

The table below shows the annual total liabilities of Intech Biopharm Ltd from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$1.25 Billion ≈ $39.38 Million	-20.96%
2024-12-31	NT$1.58 Billion ≈ $49.83 Million	+2.48%
2023-12-31	NT$1.54 Billion ≈ $48.62 Million	+1.61%
2022-12-31	NT$1.52 Billion ≈ $47.85 Million	+20.16%
2021-12-31	NT$1.26 Billion ≈ $39.82 Million	-2.22%
2020-12-31	NT$1.29 Billion ≈ $40.73 Million	+24.70%
2019-12-31	NT$1.04 Billion ≈ $32.66 Million	+1.20%
2018-12-31	NT$1.02 Billion ≈ $32.27 Million	+15.42%
2017-12-31	NT$887.48 Million ≈ $27.96 Million	--

About Intech Biopharm Ltd

TWO:6461 Taiwan Biotechnology

Market Cap

$95.93 Million

NT$3.04 Billion TWD

Market Cap Rank

#19182 Global

#1080 in Taiwan

Share Price

NT$27.60

Change (1 day)

+1.47%

52-Week Range

NT$14.40 - NT$29.20

All Time High

NT$57.64